Tuberculosis and Respiratory Diseases

  • 제85권3호
  • /
  • Pages.205-220
  • /
  • 2022
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review

  • 투고 : 2022.01.06
  • 심사 : 2022.05.23
  • 발행 : 2022.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

This study aimed to describe the prevalence of comorbidities associated with chronic obstructive pulmonary disease (COPD) and their relation with relevant outcomes. A systematic review based on the PRISMA methodology was performed from January 2020 until July 2021. The MEDLINE, Lilacs, and Scielo databases were searched to identify studies related to COPD and its comorbidities. Observational studies on the prevalence of comorbidities in COPD patients and costs with health estimates, reduced quality of life, and mortality were included. Studies that were restricted to one or more COPD pain assessments and only specific comorbidities such as osteoporosis, bronchitis, and asthma were excluded. The initial search identified 1,409 studies and after applying the inclusion and exclusion criteria, 20 studies were finally selected for analysis (comprising data from 447,459 COPD subjects). The most frequent COPD comorbidities were: hypertension (range, 17%-64.7%), coronary artery disease (19.9%-47.8%), diabetes (10.2%-45%), osteoarthritis (18%-43.8%), psychiatric conditions (12.1%-33%), and asthma (14.7%-32.5%). Several comorbidities had an impact on the frequency and severity of COPD exacerbations, quality of life, and mortality risk, in particular malignancies, coronary artery disease, chronic heart failure, and cardiac arrhythmias. Comorbidities, especially cardiovascular diseases and diabetes, are frequent in COPD patients, and some of them are associated with higher mortality.

키워드

과제정보

We would like to thank the Stricto Sensu Graduate Program in Pharmaceutical Sciences at the State University of Bahia for all the support and partnership.

참고문헌

  1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128. https://doi.org/10.1016/S0140-6736(12)61728-0
  2. Divo MJ, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, Zulueta JJ, et al. COPD comorbidities network. Eur Respir J 2015;46:640-50. https://doi.org/10.1183/09031936.00171614
  3. Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008;63:487-92. https://doi.org/10.1136/thx.2007.086371
  4. Baker CL, Zou KH, Su J. Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis 2013;8:551-9.
  5. Cavailles A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir Rev 2013;22:454-75. https://doi.org/10.1183/09059180.00008612
  6. Putcha N, Drummond MB, Wise RA, Hansel NN. Comorbidities and chronic obstructive pulmonary disease: prevalence, influence on outcomes, and management. Semin Respir Crit Care Med 2015;36:575-91. https://doi.org/10.1055/s-0035-1556063
  7. Franssen FM, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev 2014;23:131-41. https://doi.org/10.1183/09059180.00007613
  8. Martinez CH, Mannino DM, Divo MJ. Defining COPD-related comorbidities, 2004-2014. Chronic Obstr Pulm Dis 2014;1:51-63. https://doi.org/10.15326/jcopdf.1.1.2014.0119
  9. Greulich T, Weist BJ, Koczulla AR, Janciauskiene S, Klemmer A, Lux W, et al. Prevalence of comorbidities in COPD patients by disease severity in a German population. Respir Med 2017;132:132-8. https://doi.org/10.1016/j.rmed.2017.10.007
  10. Camiciottoli G, Bigazzi F, Magni C, Bonti V, Diciotti S, Bartolucci M, et al. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2016;11:2229-36. https://doi.org/10.2147/copd.s111724
  11. Maselli DJ, Bhatt SP, Anzueto A, Bowler RP, DeMeo DL, Diaz AA, et al. Clinical epidemiology of COPD: insights from 10 years of the COPDGene study. Chest 2019;156:228-38. https://doi.org/10.1016/j.chest.2019.04.135
  12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535. https://doi.org/10.1136/bmj.b2535
  13. Fuchs SC, Paim BS. Systematic review of observational studies with meta-analysis. Rev HCPA 2010;30:294-301.
  14. Quality assessment tool for observational cohort and cross-sectional studies [Internet]. Bethesda: National Heart, Lung, and Blood Institute; 2016 [cited 2016 Nov 11]. Available from: http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort.
  15. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005-11. https://doi.org/10.1378/chest.128.4.2005
  16. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-61. https://doi.org/10.1164/rccm.201201-0034OC
  17. Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and burden of COPD: a population based case-control study. PLoS One 2013;8:e63285. https://doi.org/10.1371/journal.pone.0063285
  18. Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013;107: 1376-84. https://doi.org/10.1016/j.rmed.2013.05.001
  19. Echave-Sustaeta JM, Comeche Casanova L, Cosio BG, Soler-Cataluna JJ, Garcia-Lujan R, Ribera X. Comorbidity in chronic obstructive pulmonary disease: related to disease severity? Int J Chron Obstruct Pulmon Dis 2014;9: 1307-14. https://doi.org/10.2147/COPD.S71849
  20. Ongel EA, Karakurt Z, Salturk C, Takir HB, Burunsuzoglu B, Kargin F, et al. How do COPD comorbidities affect ICU outcomes? Int J Chron Obstruct Pulmon Dis 2014;9:1187-96. https://doi.org/10.2147/COPD.S70257
  21. Diez-Manglano J, Barquero-Romero J, Almagro P, Cabrera FJ, Lopez Garcia F, Montero L, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med 2014;9:419-25. https://doi.org/10.1007/s11739-013-0945-7
  22. Koskela J, Kilpelainen M, Kupiainen H, Mazur W, Sintonen H, Boezen M, et al. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm Med 2014;14:102. https://doi.org/10.1186/1471-2466-14-102
  23. Divo MJ, Cabrera C, Casanova C, Marin JM, Pinto-Plata VM, de-Torres JP, et al. Comorbidity distribution, clinical expression and survival in COPD patients with different body mass index. Chronic Obstr Pulm Dis 2014;1:229-38. https://doi.org/10.15326/jcopdf.2.1.2014.0117
  24. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med 2015;10:24. https://doi.org/10.1186/s40248-015-0023-2
  25. Battaglia S, Basile M, Scichilone N, Bellia V. Prevalence of co-morbidities and severity of COPD. COPD 2015;12:390-4. https://doi.org/10.3109/15412555.2014.974734
  26. Mannino DM, Higuchi K, Yu TC, Zhou H, Li Y, Tian H, et al. Economic burden of COPD in the presence of comorbidities. Chest 2015;148:138-50. https://doi.org/10.1378/chest.14-2434
  27. Caram LM, Ferrari R, Naves CR, Coelho LS, Vale SA, Tanni SE, et al. Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD. J Bras Pneumol 2016;42:179-84. https://doi.org/10.1590/S1806-37562015000000121
  28. Jeong SH, Lee H, Carriere KC, Shin SH, Moon SM, Jeong BH, et al. Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients. Int J Chron Obstruct Pulmon Dis 2016;11:1857-65. https://doi.org/10.2147/COPD.S103063
  29. Deniz S, Sengul A, Aydemir Y, Celdir Emre J, Ozhan MH. Clinical factors and comorbidities affecting the cost of hospital-treated COPD. Int J Chron Obstruct Pulmon Dis 2016;11:3023-30. https://doi.org/10.2147/COPD.S120637
  30. Liao KM, Liang FW, Li CY. Risks of all-cause and site-specific fractures among hospitalized patients with COPD. Medicine (Baltimore) 2016;95:e5070. https://doi.org/10.1097/md.0000000000005070
  31. Westerik JA, Metting EI, van Boven JF, Tiersma W, Kocks JW, Schermer TR. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res 2017;18:31. https://doi.org/10.1186/s12931-017-0512-2
  32. Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, et al. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis 2017;12:735-44. https://doi.org/10.2147/COPD.S112256
  33. Divo MJ, Celli BR, Poblador-Plou B, Calderon-Larranaga A, de-Torres JP, Gimeno-Feliu LA, et al. Chronic obstructive pulmonary disease (COPD) as a disease of early aging: evidence from the EpiChron cohort. PLoS One 2018;13:e0193143. https://doi.org/10.1371/journal.pone.0193143
  34. Divo M, Celli BR. Multimorbidity in patients with chronic obstructive pulmonary disease. Clin Chest Med 2020;41:405-19. https://doi.org/10.1016/j.ccm.2020.06.002
  35. Putcha N, Puhan MA, Drummond MB, Han MK, Regan EA, Hanania NA, et al. A simplified score to quantify comorbidity in COPD. PLoS One 2014;9:e114438. https://doi.org/10.1371/journal.pone.0114438
  36. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009;135:173-80. https://doi.org/10.1378/chest.08-1419
  37. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85. https://doi.org/10.1183/09031936.00128008
  38. Halpin DM. What is asthma chronic obstructive pulmonary disease overlap? Clin Chest Med 2020;41:395-403. https://doi.org/10.1016/j.ccm.2020.06.006
  39. Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018;27:180057. https://doi.org/10.1183/16000617.0057-2018
  40. Benson VS, Mullerova H, Vestbo J, Wedzicha JA, Patel A, Hurst JR, et al. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med 2015;109:1147-54. https://doi.org/10.1016/j.rmed.2015.06.009
  41. Chalmers JD, Laska IF, Franssen FM, Janssens W, Pavord I, Rigau D, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J 2020;55:2000351. https://doi.org/10.1183/13993003.00351-2020
  42. Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, et al. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res 2020;21:240. https://doi.org/10.1186/s12931-020-01482-1
  43. Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201:e56-69.
  44. Vestbo J, Janson C, Nuevo J, Price D. Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. ERJ Open Res 2020;6:00044-2020.
  45. Mazzuco A, Souza AS, Medeiros WM, Sperandio PA, Alencar MCN, Arbex FF, et al. Effects of high- and moderate-intensity exercise on central hemodynamic and oxygen uptake recovery kinetics in CHF-COPD overlap. Braz J Med Biol Res 2020;53:e9391. https://doi.org/10.1590/1414-431x20199391
  46. Janssen DJ, Franssen FM, Wouters EF, Schols JM, Spruit MA. Impaired health status and care dependency in patients with advanced COPD or chronic heart failure. Qual Life Res 2011;20:1679-88. https://doi.org/10.1007/s11136-011-9892-9
  47. Li XF, Mao YM. Beta-blockers in COPD: a systematic review based on recent research. Life Sci 2020;252:117649. https://doi.org/10.1016/j.lfs.2020.117649
  48. Pirina P, Zinellu E, Martinetti M, Spada C, Piras B, Collu C, et al. Treatment of COPD and COPD-heart failure comorbidity in primary care in different stages of the disease. Prim Health Care Res Dev 2020;21:e16. https://doi.org/10.1017/S1463423620000079